摘要
的国内膀胱尿路上皮癌在泌尿系恶性肿瘤中较常见，其临床特点是多发和高复发率。文章探讨非肌层浸润膀胱尿路上皮癌术后二次电切预防肿瘤复发的临床疗效。方法收集南京军区南京总医院2005年2月至2010年10月期间收治的非肌层浸润性膀胱尿路上皮癌患者84例，其中38例经尿道膀胱肿瘤电切术（transurethralresectionofbladdertumor，TURBT）后4—6周入院行再次电切术（Re—TURBT），46例未行Re—TURBT，比较2组患者肿瘤复发及进展情况。结果38例患者行Re—TURBT中发现残存肿瘤15例（39．5％），残余肿瘤与原发肿瘤大小、数目、分级相关。平均随访26个月后，行Re．TURBT患者较未行Re—TURBT患者的肿瘤复发率（18．4％嬲47．8％）及进展肌层浸润性肿瘤率（5．3％椰23．9％）均显著降低（P〈0．05）。结论非肌层浸润膀胱尿路上皮癌Re—TURBT可有效减少肿瘤复发，延缓肿瘤进展。
Objective Bladder transitional cell carcinoma, the most common malignancy of the urinary system in our coun- try, is characterized by multiple lesions and a high recurrence rate. This study aimed to explore the effects of Re-transurethral resection of bladder tumor （TURBT） in patients with non-muscle invasive bladder cancer. Methods From February 2005 to October 2010 in our hospital, Re-TURBT were performed 4-6 weeks after the first TURBT in 38 non-muscle invasive bladder cancer patients. Another 46 non-muscle invasive bladder cancer patients served as controls did not receive Re-TURBT. Tumor recurrence and progression were compared between the two groups. Results Residual tumors were found in 39.5% （15/38） patients underwent Re-TURBT, which were correlated with the tumor size and numbers and the high grade. After an average observation of 26 months, the patients underwent Re-TURBT showed lower rates of recurrence （ 18.4% vs 47.8% ） and development of muscle invasive cancer （5.3% vs 23.9% ） than the patients who did not receive Re-TURBT （P 〈 0.05）. Conclusion Re-TURBT can effectively reduce tumor recurrence and delay tumor progression in patients with non-muscle invasive bladder cancer.
出处
《医学研究生学报》
CAS
北大核心
2014年第1期45-47,共3页
Journal of Medical Postgraduates
基金
国家自然科学基金(30772278)
南京军区南京总医院科研基金(2012026)
